2022
Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study
Wallach JD, Gueorguieva R, Phan H, Witkiewitz K, Wu R, O'Malley SS. Predictors of abstinence, no heavy drinking days, and a 2‐level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. Alcohol Clinical And Experimental Research 2022, 46: 1331-1339. PMID: 35616436, PMCID: PMC9887652, DOI: 10.1111/acer.14877.Peer-Reviewed Original ResearchConceptsHeavy drinking daysWeeks of treatmentAlcohol use disorderDependence Scale scoresDrinking daysScale scoreDays abstinentPredictors of abstinenceConsecutive weeksUse disordersDrinking levelsCOMBINE StudyOlder subjectsRandomized placebo-controlled trialPlacebo-controlled trialEfficacy of naltrexoneMultiple patient characteristicsTrials of medicationsBehavioral intervention studyPatient characteristicsFuture trialsBaseline variablesCombined PharmacotherapiesYoung subjectsComplete abstinence
2016
Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers
DeMartini KS, Gueorguieva R, Leeman RF, Corbin WR, Fucito LM, Kranzler HR, O’Malley S. Longitudinal Findings From a Randomized Clinical Trial of Naltrexone for Young Adult Heavy Drinkers. Journal Of Consulting And Clinical Psychology 2016, 84: 185-190. PMID: 26654213, PMCID: PMC4941818, DOI: 10.1037/ccp0000053.Peer-Reviewed Original ResearchConceptsPercent days abstinentFirst placebo-controlled trialPercent days heavy drinkingHeavy drinkingPlacebo-controlled trialLong-term outcomesHeavy drinking daysYoung adults ages 18Adults ages 18Naltrexone conditionActive medicationPlacebo groupPharmacotherapy trialsAdult heavy drinkersYoung adult heavy drinkersNonsignificant decreaseSignificant benefitsYear posttreatmentDays abstinentDrinking daysMost outcomesSingle interventionHeavy drinkersTreatment improvementAge 18
2015
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. The Journal Of Clinical Psychiatry 2015, 76: e207-13. PMID: 25742208, PMCID: PMC4442987, DOI: 10.4088/jcp.13m08934.Peer-Reviewed Original ResearchConceptsHeavy drinking daysBlood alcohol concentrationPercent days abstinentDrinking daysNumber of drinksYoung adultsDays abstinentPercent heavy drinking daysOutpatient research centerSafety of naltrexonePlacebo-controlled studySerious adverse eventsRisk-benefit ratioPercentage of daysAdverse eventsSecondary outcomesPrimary outcomeFrequency of drinkingOpioid antagonistAdult heavy drinkersAlcohol drinkingClinical trialsEvaluable samplesYoung adult heavy drinkersTreatment period
2013
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking days
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply